.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Cipla
Citi
Cantor Fitzgerald
Harvard Business School
AstraZeneca
Cerilliant
Chubb
Healthtrust
Fish and Richardson

Generated: July 26, 2017

DrugPatentWatch Database Preview

DEPO-SUBQ PROVERA 104 Drug Profile

« Back to Dashboard

What is the patent landscape for Depo-subq Provera 104, and what generic Depo-subq Provera 104 alternatives are available?

Depo-subq Provera 104 is a drug marketed by Pharmacia And Upjohn and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-eight patent family members in twenty-eight countries.

The generic ingredient in DEPO-SUBQ PROVERA 104 is medroxyprogesterone acetate. There are nineteen drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the medroxyprogesterone acetate profile page.

Summary for Tradename: DEPO-SUBQ PROVERA 104

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list41
Clinical Trials: see list405
Patent Applications: see list7,137
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:DEPO-SUBQ PROVERA 104 at DailyMed

Pharmacology for Tradename: DEPO-SUBQ PROVERA 104

Ingredient-typeProgesterone Congeners
Drug ClassProgestin
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn
DEPO-SUBQ PROVERA 104
medroxyprogesterone acetate
INJECTABLE;SUBCUTANEOUS021583-001Dec 17, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: DEPO-SUBQ PROVERA 104

Country Document Number Estimated Expiration
Eurasian Patent Organization200201208► Subscribe
Czech Republic303872► Subscribe
World Intellectual Property Organization (WIPO)0187266► Subscribe
Spain2254443► Subscribe
Norway332215► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.



Supplementary Protection Certificates for Tradename: DEPO-SUBQ PROVERA 104

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0037Belgium► SubscribePRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
AstraZeneca
Colorcon
Chinese Patent Office
Cipla
US Department of Justice
Express Scripts
Novartis
Queensland Health
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot